Innate Pharma S.A. IPHA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.59% | 29.14% | 0.43% | -34.33% | -7.85% |
| Total Depreciation and Amortization | -0.59% | -9.29% | -0.43% | -1.37% | 7.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.59% | -140.46% | -0.43% | -42.90% | 7.85% |
| Change in Net Operating Assets | 0.59% | -134.55% | -0.43% | 125.75% | -7.85% |
| Cash from Operations | 0.59% | 2.04% | 0.43% | 28.63% | -7.85% |
| Capital Expenditure | 0.76% | -10.48% | 0.42% | -45.59% | -7.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.59% | 436.65% | -0.43% | -94.18% | 7.85% |
| Cash from Investing | -0.60% | 547.90% | -0.43% | -95.35% | 7.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 46.94% | 0.00% | 0.02% | 0.00% |
| Issuance of Common Stock | -- | -- | 0.00% | -99.67% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.59% | 46.07% | 0.43% | -143.33% | 7.85% |
| Foreign Exchange rate Adjustments | 0.61% | -463.64% | -0.49% | -92.95% | 7.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.59% | 15.11% | 0.43% | -107.87% | -7.85% |